Advisory Committee on Immunization Practices (ACIP), 32754-32755 [2016-12150]

Download as PDF sradovich on DSK3TPTVN1PROD with NOTICES 32754 Federal Register / Vol. 81, No. 100 / Tuesday, May 24, 2016 / Notices comments received in advance of the meeting will be included in the official record of the meeting. The public is also welcome to listen to the meeting by joining the teleconference at the USA toll-free, dial-in number at 1–866–659– 0537 and the pass code is 9933701. Background: The Advisory Board was established under the Energy Employees Occupational Illness Compensation Program Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Key functions of the Advisory Board include providing advice on the development of probability of causation guidelines that have been promulgated by the Department of Health and Human Services (HHS) as a final rule; advice on methods of dose reconstruction, which have also been promulgated by HHS as a final rule; advice on the scientific validity and quality of dose estimation and reconstruction efforts being performed for purposes of the compensation program; and advice on petitions to add classes of workers to the Special Exposure Cohort (SEC). In December 2000, the President delegated responsibility for funding, staffing, and operating the Advisory Board to HHS, which subsequently delegated this authority to CDC. NIOSH implements this responsibility for CDC. The charter was issued on August 3, 2001, renewed at appropriate intervals, rechartered on March 22, 2016 pursuant to Executive Order 13708, and will expire on September 30, 2017. Purpose: The Advisory Board is charged with (a) providing advice to the Secretary, HHS, on the development of guidelines under Executive Order 13179; (b) providing advice to the Secretary, HHS, on the scientific validity and quality of dose reconstruction efforts performed for this program; and (c) upon request by the Secretary, HHS, advise the Secretary on whether there is a class of employees at any Department of Energy facility who were exposed to radiation but for whom it is not feasible to estimate their radiation dose, and on whether there is reasonable likelihood that such radiation doses may have endangered the health of members of this class. The Subcommittee for Dose Reconstruction Reviews was established to aid the Advisory Board in carrying out its duty to advise the Secretary, HHS, on dose reconstruction. Matters for Discussion: The agenda for the Subcommittee meeting includes the following dose reconstruction program quality management and assurance activities: dose reconstruction cases VerDate Sep<11>2014 17:24 May 23, 2016 Jkt 238001 under review from Sets 14–18, including the Oak Ridge sites (Y–12, K– 25, Oak Ridge National Laboratory), Hanford, Feed Materials Production Center (‘‘Fernald’’), Mound Plant, Rocky Flats Plant, Nevada Test Site, Idaho National Laboratory, and Savannah River Site; preparation of the Advisory Board’s next report to the Secretary, HHS, summarizing the results of completed dose reconstruction reviews. The agenda is subject to change as priorities dictate. Contact Person for More Information: Theodore Katz, Designated Federal Officer, NIOSH, CDC, 1600 Clifton Road, Mailstop E–20, Atlanta, Georgia 30333, Telephone (513) 533–6800, Toll Free 1 (800) CDC–INFO, Email ocas@ cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2016–12149 Filed 5–23–16; 8:45 am] BILLING CODE 4163–19–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announce the following meeting of the aforementioned committee. Time and Date 8:00 a.m.–6:00 p.m., EDT, June 22, 2016 8:00 a.m.–5:00 p.m., EDT, June 23, 2016 Place: CDC, Tom Harkin Global Communications Center, 1600 Clifton Road, NE., Building 19, Kent ‘‘Oz’’ Nelson Auditorium, Atlanta, Georgia 30329. Status: Open to the public, limited only by the space available. Time will be available for public comment. The public is welcome to submit written comments in advance of the meeting. Comments should be submitted in writing by email to the contact person listed below. The deadline for receipt June 13, 2016. All requests must contain PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 the name, address, and organizational affiliation of the speaker, as well as the topic being addressed. Written comments should not exceed one singlespaced typed page in length and delivered in 3 minutes or less. Please note that the public comment period may end before the time indicated, following the last call for comments. Members of the public who wish to provide public comments should plan to attend the public comment session at the start time listed. Written comments received in advance of the meeting will be included in the official record of the meeting. The meeting will be webcast live via the World Wide Web; for instructions and more information on ACIP please visit the ACIP Web site: https:// www.cdc.gov/vaccines/acip/. Purpose: The committee is charged with advising the Director, CDC, on the appropriate use of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines. Further, under provisions of the Affordable Care Act, at section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been adopted by the Director of the Centers for Disease Control and Prevention and appear on the CDC immunization schedules must be covered by applicable health plans. Matters for Discussion: The agenda will include discussions on: Meningococcal vaccines; human papillomavirus vaccines; influenza; cholera vaccine; hepatitis vaccines; safety of maternal Tdap vaccination; child/adolescent immunization schedule; Respiratory Syncytial Virus (RSV) and vaccine supply. A recommendation vote is scheduled for meningococcal vaccines and cholera vaccine. A Vaccines for Children (VFC) vote is scheduled for meningococcal vaccines. Agenda items are subject to change as priorities dictate. Contact Person for More Information: Stephanie Thomas, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road, NE., MS–A27, Atlanta, Georgia 30329, telephone 404/ 639–8836; Email ACIP@CDC.GOV. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of E:\FR\FM\24MYN1.SGM 24MYN1 Federal Register / Vol. 81, No. 100 / Tuesday, May 24, 2016 / Notices meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2016–12150 Filed 5–23–16; 8:45 am] BILLING CODE 4160–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention sradovich on DSK3TPTVN1PROD with NOTICES Safety and Occupational Health Study Section (SOHSS), National Institute for Occupational Safety and Health (NIOSH or Institute) In accordance with section 10(a)(2) of the Federal Advisory Committee Act (P. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting. Times and Dates: 8:00 a.m.–5:00 p.m., EDT, June 14, 2016 (Closed); 8:00 a.m.– 5:00 p.m., EDT, June 15, 2016 (Closed). Place: Embassy Suites, 1900 Diagonal Road, Alexandria, Virginia 22314, Telephone: 703–684–5900, Fax: 703– 684–0653. Purpose: The Safety and Occupational Health Study Section will review, discuss, and evaluate grant application(s) received in response to the Institute’s standard grants review and funding cycles pertaining to research issues in occupational safety and health, and allied areas. It is the intent of NIOSH to support broad-based research endeavors in keeping with the Institute’s program goals. This will lead to improved understanding and appreciation for the magnitude of the aggregate health burden associated with occupational injuries and illnesses, as well as to support more focused research projects, which will lead to improvements in the delivery of occupational safety and health services, and the prevention of work-related injury and illness. It is anticipated that research funded will promote these program goals. Matters for Dicussion: The meeting will convene to address matters related to the conduct of Study Section business and for the study section to consider safety and occupational healthrelated grant applications. These portions of the meeting will be closed to the public in accordance with provisions set forth in Section VerDate Sep<11>2014 17:24 May 23, 2016 Jkt 238001 32755 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, Centers for Disease Control and Prevention, pursuant to Section 10(d) Pub. L. 92–463. Agenda items are subject to change as priorities dictate. Person for More Information: Price Connor, Ph.D., NIOSH Health Scientist, CDC, 2400 Executive Parkway, Mailstop E–20, Atlanta, Georgia 30345, Telephone: 404–498–2511, Fax: 404– 498–2571. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and (e) Assess information collection costs. To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639–7570 or send an email to omb@cdc.gov. Written comments and/or suggestions regarding the items contained in this notice should be directed to the Attention: CDC Desk Officer, Office of Management and Budget, Washington, DC 20503 or by fax to (202) 395–5806. Written comments should be received within 30 days of this notice. Elaine L. Baker, Director, Management Analysis and Services Office Centers for Disease Control and Prevention. Proposed Project Ingress/Egress and Work Boot Outsole Wear Investigation at Surface Mines— New—National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC). [FR Doc. 2016–12225 Filed 5–23–16; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [30Day–16–16GK] Agency Forms Undergoing Paperwork Reduction Act Review The Centers for Disease Control and Prevention (CDC) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The notice for the proposed information collection is published to obtain comments from the public and affected agencies. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address any of the following: (a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) Enhance the quality, utility, and clarity of the information to be collected; (d) Minimize the burden of PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 Background and Brief Description The mission of the National Institute for Occupational Safety and Health (NIOSH) is to promote safety & health at work for all people through research and prevention. NIOSH, under PL 91– 173 as amended by PL 95–164 (Federal Mine Safety and Health Act of 1977) has the responsibility to conduct research to improve working conditions and to prevent accidents and occupational diseases in the U.S. mining sector. The goal of the proposed project is to investigate how ingress/egress systems on mobile equipment, and personal protective footwear (boots) used by miners may lead to slips, trips and falls at stone, sand and gravel surface mining facilities. NIOSH is requesting a threeyear approval for this data collection. The project objective will be achieved through two studies. The first study aims to: Identify elements of ingress/ egress systems on haulage trucks and front end loaders that pose a risk of slips, trips and falls (STFs) and could lead to STF related injuries; to determine worker behavior associated with STF incidents; and to learn how purchasing/maintenance decisions are made for ingress/egress systems. In the surface mining industry, it is still unclear which component of the ingress/egress system poses the greatest risk for STF. Hence there is a need to understand where, how and why STF incidents occur during ingress/egress on mobile equipment. E:\FR\FM\24MYN1.SGM 24MYN1

Agencies

[Federal Register Volume 81, Number 100 (Tuesday, May 24, 2016)]
[Notices]
[Pages 32754-32755]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-12150]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Advisory Committee on Immunization Practices (ACIP)

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announce the following meeting of the aforementioned 
committee.

Time and Date

8:00 a.m.-6:00 p.m., EDT, June 22, 2016
8:00 a.m.-5:00 p.m., EDT, June 23, 2016

    Place: CDC, Tom Harkin Global Communications Center, 1600 Clifton 
Road, NE., Building 19, Kent ``Oz'' Nelson Auditorium, Atlanta, Georgia 
30329.
    Status: Open to the public, limited only by the space available. 
Time will be available for public comment. The public is welcome to 
submit written comments in advance of the meeting. Comments should be 
submitted in writing by email to the contact person listed below. The 
deadline for receipt June 13, 2016. All requests must contain the name, 
address, and organizational affiliation of the speaker, as well as the 
topic being addressed. Written comments should not exceed one single-
spaced typed page in length and delivered in 3 minutes or less. Please 
note that the public comment period may end before the time indicated, 
following the last call for comments. Members of the public who wish to 
provide public comments should plan to attend the public comment 
session at the start time listed. Written comments received in advance 
of the meeting will be included in the official record of the meeting.
    The meeting will be webcast live via the World Wide Web; for 
instructions and more information on ACIP please visit the ACIP Web 
site: https://www.cdc.gov/vaccines/acip/.
    Purpose: The committee is charged with advising the Director, CDC, 
on the appropriate use of immunizing agents. In addition, under 42 
U.S.C. 1396s, the committee is mandated to establish and periodically 
review and, as appropriate, revise the list of vaccines for 
administration to vaccine-eligible children through the Vaccines for 
Children (VFC) program, along with schedules regarding the appropriate 
periodicity, dosage, and contraindications applicable to the vaccines. 
Further, under provisions of the Affordable Care Act, at section 2713 
of the Public Health Service Act, immunization recommendations of the 
ACIP that have been adopted by the Director of the Centers for Disease 
Control and Prevention and appear on the CDC immunization schedules 
must be covered by applicable health plans.
    Matters for Discussion: The agenda will include discussions on: 
Meningococcal vaccines; human papillomavirus vaccines; influenza; 
cholera vaccine; hepatitis vaccines; safety of maternal Tdap 
vaccination; child/adolescent immunization schedule; Respiratory 
Syncytial Virus (RSV) and vaccine supply. A recommendation vote is 
scheduled for meningococcal vaccines and cholera vaccine. A Vaccines 
for Children (VFC) vote is scheduled for meningococcal vaccines.
    Agenda items are subject to change as priorities dictate.
    Contact Person for More Information: Stephanie Thomas, National 
Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton 
Road, NE., MS-A27, Atlanta, Georgia 30329, telephone 404/639-8836; 
Email ACIP@CDC.GOV.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of

[[Page 32755]]

meetings and other committee management activities for both the Centers 
for Disease Control and Prevention and the Agency for Toxic Substances 
and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2016-12150 Filed 5-23-16; 8:45 am]
 BILLING CODE 4160-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.